Physician profile
Amy Boren
NPI 1003307919
$2,081.56
in general payments reported to CMS, 2019-2025
17 companies · $208 in 2025
The $208 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.09 · 2020: $132 · 2021: $118 · 2022: $639 · 2023: $504 · 2024: $466 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,178.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $813.73 | 2023-2025 | Ubrelvy, Qulipta, Botox |
| Genentech USA, INC. | $171.47 | 2019-2024 | Ocrevus Zunovo |
| Horizon Therapeutics Plc | $121.83 | 2022 | |
| Adamas Pharmaceuticals, INC. | $120.35 | 2020 | |
| Alexion Pharmaceuticals, INC. | $118.18 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $118.08 | 2022 | |
| Genzyme Corporation | $116.68 | 2022 | |
| Argenx US, INC. | $109.93 | 2023-2025 | Vyvgart |
| Biogen, INC. | $90.30 | 2022-2023 | Tysabri |
| Teva Pharmaceuticals USA, INC. | $82.14 | 2024 | Austedo Xr |
| Tg Therapeutics, INC. | $80.84 | 2024 | |
| Sk Life Science, INC. | $33.13 | 2024 | |
| Livanova USA, INC. | $25.88 | 2022 | |
| Celgene Corporation | $25.19 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.93 | 2024 | Rexulti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $18.11 | 2022 | |
| Lilly USA, LLC | $14.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Boren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.